MONTREAL, Feb. 14, 2014 /CNW Telbec/ - Valeant Canada is proud to
participate in ARTERIA, an innovative research program aiming to
improve treatment for patients suffering from cardiovascular diseases.
ARTERIA's partners include the Montreal Heart Institute, pharmaceutical
companies such as Valeant Canada, and the Government of Quebec.
"Cardiovascular diseases account for 30% of the causes of death in the
world, and affect 1.3 million Canadians. We are proud to collaborate
with world-class partners, and put our talents and efforts together in
offering patients a more personalized treatment, adapted to their
genetics. This project is a perfect example of how Valeant wants to get
involved in research in Quebec and Canada. More than ever, we can say
that the patient is at the heart of our efforts," says Valeant Canada
President and General Manager Jacques Dessureault.
ARTERIA is an integrated approach that, in addition to gathering
expertise from all partners involved, will include genetic and plasma
biomarker analysis, and make use of state-of-the-art imaging
technologies. It will help select patients who need a specific
treatment. As a result, the medical team will be able to provide a more
adapted patient care, increasing the efficacy of the treatment and
reducing its side effects. While improving the efficacy and safety of
several drugs, ARTERIA will help the Quebec healthcare system save
money. It will create new jobs and encourage knowledge sharing among
About Valeant Canada
Valeant Canada is a subsidiary of Valeant Pharmaceuticals International
Inc., a multinational specialty pharmaceutical company that develops,
manufactures, and markets a broad range of pharmaceutical products,
primarily in the areas of dermatology, eye health, neurology, and
branded generics. More information about Valeant Canada can be found
SOURCE: Valeant Canada
For further information:
Valeant Canada Inc.